The Food and Drug Administration approved Sanofi's new drug Adlyxin to treat adults with type 2 diabetes.
Adlyxin does not contain insulin. It is an injectable prescription drug that may improve blood sugar control in adults with type 2 diabetes when paired with diet and exercise.
Sanofi will offer Adlyxin as a single dose in a disposable pre-filled pen. Patients inject the drug once a day.
Adlyxin has already been approved in more than 60 countries around the world. The Paris-based drugmaker did not say when the treatment would hit the U.S. market.
More articles on the drug market:
FDA approves AbbVie's drug to treat chronic hepatitis C
Sen. Bernie Sanders' DNC speech tackles high prescription drug costs: 4 things to know
'Pain refugees' travel out of Montana for access to opioid prescriptions